N. P. King

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

This study shows that structural flexibility in computationally designed protein assemblies leads to multiple architectures, expanding their functional possibilities.

This study characterizes the receptor tropism and antigenicity of a clade 3 sarbecovirus, identifying broad ACE2 usage and cross-neutralizing antibodies with implications for vaccine design.

This study benchmarks ProteinMPNN against Rosetta in designing two-component protein nanomaterials, showing comparable success with significantly reduced computation and no manual refinement.

This paper develops a modular saponin-based nanoparticle adjuvant platform incorporating TLR agonists, showing improved vaccine potency and breadth against COVID-19 and HIV in mice.

This study shows that antigen spacing on protein nanoparticles affects antibody responses to vaccination, with decreased spacing improving hemagglutination inhibition and neutralization potency.

This study evaluates trihead nanoparticle immunogens to enhance cross-neutralizing antibody responses against influenza H1 viruses by combining immunofocusing techniques.

This paper designs pH-responsive antibody nanoparticles with three distinct protein components that disassemble at tunable pH levels, enabling targeted delivery of biologics.

This study identifies potent pan-sarbecovirus neutralizing antibodies from vaccinated macaques, showing broad neutralization against SARS-CoV-2 variants and related viruses.

This study develops a single-dose SARS-CoV-2 subunit vaccine using hydrogel technology that generates rapid, broad, and durable humoral immunity compared to traditional multi-dose regimens.

This paper designs ice-binding proteins with controlled under-twisting of alpha-helices to enhance ice recrystallization inhibition.

RPXDock enables fast, flexible protein docking for symmetric architectures, supporting diverse applications in nanomaterial design.

This study identifies cryptic transmembrane domains in designed protein nanoparticles that hinder secretion and introduces a computational tool, Degreaser, to remove them while maintaining stability, improving secretion efficiency.

A deep learning method for protein sequence design shows high performance in both simulations and experiments, applicable to various design challenges.

This paper describes a remote cohort-based curriculum for undergraduate students to learn computational protein design, enhancing their research skills and connecting them with the lab.

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

This study evaluates a nanoparticle vaccine displaying EBV gH/gL, showing it protects humanized mice against lethal EBV challenge, while monomeric gH/gL does not.

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

This paper qualifies ELISA and neutralization assays to measure SARS-CoV-2 humoral immunity using clinical samples, evaluating antibody titers and functional neutralization capacity.

This study designs stabilized recombinant influenza neuraminidase tetramers by uncovering structural principles and improving thermal stability and antibody affinity.

This paper designs stabilized SARS-CoV-2 RBD variants using deep mutational scanning and structure-based design, showing improved thermal stability and manufacturability for vaccine applications.

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

The paper uses cryoEM to analyze polyclonal antibody responses to HIV Env immunogens in rhesus macaques, revealing structural differences in antibody binding and immunogenicity of engineered mutations and glycan sites.

The paper designs modular nanocages that assemble antibodies into precise geometries, enhancing signaling and neutralization compared to free antibodies.

This study shows that displaying HIV-1 Env trimers on two-component protein nanoparticles enhances autologous Tier-2 neutralizing antibody titers in rabbits.

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

Nanoparticle immunogens with four seasonal influenza hemagglutinins elicit neutralizing antibodies against both the head and stem, providing broad protection against diverse influenza strains.

This paper provides a protocol for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein to measure neutralizing antibody activity in a luciferase-based assay.

This study shows that HIV Env immunogens can be concentrated in B cell follicles using immune complexes or protein nanoparticles, enhancing their localization in lymph nodes and potentially improving immune responses.